The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial?
Inhye Ahn, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the limitations of continuous BTK inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL), explaining how combination therapies with BTKis, BCL2 inhibitors, and monoclonal antibodies may allow more time-limited therapies. Dr Ahn mentions that it could be feasible to stop BTKi therapy in CLL. However, she notes that there is still more work to be done to fully understand time-limited BTKi therapy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
